Iskra Bayraktarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Iskra Bayraktarova has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Elina Trendafilova
National Heart Hospital, Sofia, Bulgaria
3 shared publications - Alexander Alexandrov
National Heart Hospital -Sofi a Резюме
2 shared publications - B. Georgiev
National Heart Hospital, Sofia, Bulgaria
1 shared publication - Dimitar Kyuchukov
National Heart Hospital, Sofia, Bulgaria
1 shared publication - E. Kostova-Dimitrova
National Heart Hospital -Sofi a Резюме
1 shared publication - Elena Dimitrova
National Cardiology Hospital Sofia, 1309 Sofia, Bulgaria
1 shared publication
Latest Publications
- Open Access
- 31 December 2025
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 31 (4) , 136-155
Psychogenic pseudosyncope – when the cardiologist gives the diagnosis, but not the treatment. case report and review of the literature
Psychogenic pseudosyncope is a state of apparent loss of consciousness, which is indistinguishable from true loss of consciousness by eyewitnesses. However, there are no hemodynamic and electroencephalographic stigmata of true syncope with real loss of consciousness. Sometimes a detailed history can raise doubts about the condition – a relatively long period of unconsciousness, unusual triggers, atypical prodromes and frequent attacks are suspicious signs, but they are far from specifi c in the population of patients presenting for differential diagnosis of syncopal episodes to the cardiologist. The gold standard for making the diagnosis is the provocation with a tilt-table test, in which psychogenic pseudosyncope is registered and simultaneously the absence of hemodynamic (and in the optimal case, electroencephalographic) signs of loss of consciousness is objectifi ed. It should be noted that the presence of psychogenic pseudosyncope does not automatically exclude the presence of true refl ex syncope in the particular patient. Treatment based primarily on a clear explanation of the condition and supportive communication with the patient can lead to a sharp reduction in the frequency of attacks. Pharmacological treatment of associated psychiatric disorders, as well as psychological support, is extremely effective. Cognitive-behavioural therapy is the most preferred approach in this patient population. In this review, we will present the diagnostic process in one patient and discuss the development of the understanding of this condition, the main clinical features and diagnostic approaches, the classifi cation and underlying pathology, as well as therapeutic methods.
- 31 December 2025
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 31 (4) , 136-155
Open AccessPsychogenic pseudosyncope – when the cardiologist gives the diagnosis, but not the treatment. case report and review of the literature
Psychogenic pseudosyncope is a state of apparent loss of consciousness, which is indistinguishable from true loss of consciousness by eyewitnesses. However, there are no hemodynamic and electroencephalographic stigmata of true syncope with real loss of consciousness. Sometimes a detailed history can raise doubts about the condition – a relatively long period of unconsciousness, unusual triggers, atypical prodromes and frequent attacks are suspicious signs, but they are far from specifi c in the population of patients presenting for differential diagnosis of syncopal episodes to the cardiologist. The gold standard for making the diagnosis is the provocation with a tilt-table test, in which psychogenic pseudosyncope is registered and simultaneously the absence of hemodynamic (and in the optimal case, electroencephalographic) signs of loss of consciousness is objectifi ed. It should be noted that the presence of psychogenic pseudosyncope does not automatically exclude the presence of true refl ex syncope in the particular patient. Treatment based primarily on a clear explanation of the condition and supportive communication with the patient can lead to a sharp reduction in the frequency of attacks. Pharmacological treatment of associated psychiatric disorders, as well as psychological support, is extremely effective. Cognitive-behavioural therapy is the most preferred approach in this patient population. In this review, we will present the diagnostic process in one patient and discuss the development of the understanding of this condition, the main clinical features and diagnostic approaches, the classifi cation and underlying pathology, as well as therapeutic methods.
- Open Access
- 31 December 2025
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 31 (4) , 52-86
Echocardiography in hypertrophic cardiomyopathy – still a chief diagnostic tool
Hypertrophic cardiomyopathy is one of the most common hereditary cardiomyopathies in daily practice. The different phenotypic manifestations and hemodynamic features often make diagnosis and therapy a clinical challenge. Diagnosis and imaging follow-up of cardiomyopathies are becoming increasingly multimodal. Despite the new imaging capabilities, echocardiography continues to play a key role in the primary differential diagnostic process, in the follow-up of patients, regardless of the therapeutic approach taken, and in the screening of relatives. Therefore, good knowledge of echocardiographic methods for assessment in these patients, of practical features and possible errors during the examination, is an essential prerequisite for high quality care. Precise systematic measurements and descriptions of the fi nding in each patient are the basis of good follow-up, adequate management planning and reassessment of therapy, and of seamless team care for the patient by various specialists. Confl icting or inconsistent imaging fi ndings, discrepancies in imaging fi ndings and clinical presentation, and the need for specialized therapy are valid reasons for referring the patient for a staged evaluation to an expert center for HCM.
- 31 December 2025
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 31 (4) , 52-86
Open AccessEchocardiography in hypertrophic cardiomyopathy – still a chief diagnostic tool
Hypertrophic cardiomyopathy is one of the most common hereditary cardiomyopathies in daily practice. The different phenotypic manifestations and hemodynamic features often make diagnosis and therapy a clinical challenge. Diagnosis and imaging follow-up of cardiomyopathies are becoming increasingly multimodal. Despite the new imaging capabilities, echocardiography continues to play a key role in the primary differential diagnostic process, in the follow-up of patients, regardless of the therapeutic approach taken, and in the screening of relatives. Therefore, good knowledge of echocardiographic methods for assessment in these patients, of practical features and possible errors during the examination, is an essential prerequisite for high quality care. Precise systematic measurements and descriptions of the fi nding in each patient are the basis of good follow-up, adequate management planning and reassessment of therapy, and of seamless team care for the patient by various specialists. Confl icting or inconsistent imaging fi ndings, discrepancies in imaging fi ndings and clinical presentation, and the need for specialized therapy are valid reasons for referring the patient for a staged evaluation to an expert center for HCM.
- Open Access
- 11 December 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 30 (3) , 7-28
Echocardiography in acute pulmonary embolism – what do we have?
Pulmonary thromboembolism (PE) related mortality worldwide is decreasing due to current therapeutic advances. However, PE remains the third leading cause of death in developed countries and its incidence is increasing. Timely diagnosis and appropriate therapeutic measures are extremely important in clinical practice. Echocardiography (EchoCG) remains a preferred imaging technique at the bedside for both primary diagnosis and individual patient risk determination, and provides invaluable information regarding general hemodynamics in emergency situations. The development of the methodology in recent years adds new parameters to the classic image of the patient with PE. In this review, modern approaches for risk stratification of patients with PE by means of echocardiography and the role of echocardiography in the diagnosis of the disease are considered.
- 11 December 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 30 (3) , 7-28
Open AccessEchocardiography in acute pulmonary embolism – what do we have?
Pulmonary thromboembolism (PE) related mortality worldwide is decreasing due to current therapeutic advances. However, PE remains the third leading cause of death in developed countries and its incidence is increasing. Timely diagnosis and appropriate therapeutic measures are extremely important in clinical practice. Echocardiography (EchoCG) remains a preferred imaging technique at the bedside for both primary diagnosis and individual patient risk determination, and provides invaluable information regarding general hemodynamics in emergency situations. The development of the methodology in recent years adds new parameters to the classic image of the patient with PE. In this review, modern approaches for risk stratification of patients with PE by means of echocardiography and the role of echocardiography in the diagnosis of the disease are considered.
- Open Access
- 12 January 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (4) , 61-72
Cardioneuroablation for recurrent vasovagal syncope and functional sinus bradycardia: a case series
При пациенти с рецидивиращ вазовагален синкоп с кардиоинхибиторен или смесен механизъм, или при пациенти със симптомна функционална синусова брадикардия или АV блок може да се приложи кардионевроаблация. Материал и методи: Представяме серия от 5 пациенти – четирима от тях с рецидивиращи синкопи и/или симптомна синусова брадикардия, а петият – с пристъпно предсърдно мъждене и рецидивиращи синкопи. След потвърждение на механизма на синкопа с тилт-тест и след положителен атропинов тест беше извършена радиофреквентна катетърна кардионевроаблация (при пациента с предсърдно мъждене като добавка към изолация на белодробните вени). При краткосрочно проследяване при нито един от пациентите няма рецидив на синкоп. Заключение: Катетърната невромодулация в тази първа в България клинична серия показва много добри краткосрочни резултати и липса на сериозни усложнения. Patients with recurrent vasovagal syncope with cardioinhibitory or mixed mechanism, or with symptomatic functional sinus bradycardia or AV block can be treated with cardioneuroablation. Material and methods: A case series of 5 patients is presented – four with recurrent syncope and/or symptomatic sinus bradycardia, and one with paroxysmal atrial fi brillation and recurrent syncope. After a confi rmation of the syncope mechanism with tilt table test, and after positive atropine test, radiofrequency catheter cardioneuroablation was performed (this was adjunctive procedure for the patient with atrial fi brillation who received pulmonary vein isolation). During short-term follow-up none of the patients had syncopal recurrence. Conclusion: Catheter neuromodulation provided very good short-term results and lack of serious complications in this fi rst case series in Bulgaria.
- 12 January 2024
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (4) , 61-72
Open AccessCardioneuroablation for recurrent vasovagal syncope and functional sinus bradycardia: a case series
При пациенти с рецидивиращ вазовагален синкоп с кардиоинхибиторен или смесен механизъм, или при пациенти със симптомна функционална синусова брадикардия или АV блок може да се приложи кардионевроаблация. Материал и методи: Представяме серия от 5 пациенти – четирима от тях с рецидивиращи синкопи и/или симптомна синусова брадикардия, а петият – с пристъпно предсърдно мъждене и рецидивиращи синкопи. След потвърждение на механизма на синкопа с тилт-тест и след положителен атропинов тест беше извършена радиофреквентна катетърна кардионевроаблация (при пациента с предсърдно мъждене като добавка към изолация на белодробните вени). При краткосрочно проследяване при нито един от пациентите няма рецидив на синкоп. Заключение: Катетърната невромодулация в тази първа в България клинична серия показва много добри краткосрочни резултати и липса на сериозни усложнения. Patients with recurrent vasovagal syncope with cardioinhibitory or mixed mechanism, or with symptomatic functional sinus bradycardia or AV block can be treated with cardioneuroablation. Material and methods: A case series of 5 patients is presented – four with recurrent syncope and/or symptomatic sinus bradycardia, and one with paroxysmal atrial fi brillation and recurrent syncope. After a confi rmation of the syncope mechanism with tilt table test, and after positive atropine test, radiofrequency catheter cardioneuroablation was performed (this was adjunctive procedure for the patient with atrial fi brillation who received pulmonary vein isolation). During short-term follow-up none of the patients had syncopal recurrence. Conclusion: Catheter neuromodulation provided very good short-term results and lack of serious complications in this fi rst case series in Bulgaria.
- Open Access
- 31 December 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (4) , 111-124
Systemic thrombolysis for mechanical prosthetic valve thrombosis - case report and review of literature
Тромбозата на клапна протеза е едно от потенциално животозастрашаващите усложнения при клапнопротезирани пациенти. То се среща най-често при наличие на механична протеза и субтерапевтична или липсваща антикоагулация. Освен оптимизиране на антикоагулантната терапия в съображение влизат спешно хирургично лечение и тромболитична терапия, като и двете са свързани с висок риск за усложнения и смъртност. Представяме пациент с доказана тромбоза на механична митрална протеза. На базата на индивидуалните му характеристики и публикуваните препоръки взехме решение за системна фибринолиза с тъканен плазминогенен активатор по много бавен нискодозов протокол. Отчетохме добър ефект при липса на хеморагични и емболични усложения. Prosthetic valve thrombosis is one of the life-threatening complications in patients with prosthetic heart valves. It is more common in mechanical prosthetic valves in the setting of inadequate or missing anticoagulation. Besides optimization of anticoagulation urgent surgery or thrombolytic therapy should be considered but both are associated with an increased risk for complications and mortality. We report a case of a patient with imaging data for mechanical prosthetic mitral valve thrombosis. Considering the individual patient’s characteristics and the published guidelines we decided to perform systemic thrombolysis with ultra-slow low-dose infusion of tissue-type plasminogen activator. The therapy was successful without any bleeding or thromboembolic complications.
- 31 December 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (4) , 111-124
Open AccessSystemic thrombolysis for mechanical prosthetic valve thrombosis - case report and review of literature
Тромбозата на клапна протеза е едно от потенциално животозастрашаващите усложнения при клапнопротезирани пациенти. То се среща най-често при наличие на механична протеза и субтерапевтична или липсваща антикоагулация. Освен оптимизиране на антикоагулантната терапия в съображение влизат спешно хирургично лечение и тромболитична терапия, като и двете са свързани с висок риск за усложнения и смъртност. Представяме пациент с доказана тромбоза на механична митрална протеза. На базата на индивидуалните му характеристики и публикуваните препоръки взехме решение за системна фибринолиза с тъканен плазминогенен активатор по много бавен нискодозов протокол. Отчетохме добър ефект при липса на хеморагични и емболични усложения. Prosthetic valve thrombosis is one of the life-threatening complications in patients with prosthetic heart valves. It is more common in mechanical prosthetic valves in the setting of inadequate or missing anticoagulation. Besides optimization of anticoagulation urgent surgery or thrombolytic therapy should be considered but both are associated with an increased risk for complications and mortality. We report a case of a patient with imaging data for mechanical prosthetic mitral valve thrombosis. Considering the individual patient’s characteristics and the published guidelines we decided to perform systemic thrombolysis with ultra-slow low-dose infusion of tissue-type plasminogen activator. The therapy was successful without any bleeding or thromboembolic complications.
- Open Access
- 7 April 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (1) , 65-75
Impact of baseline anemia on the short- and long-term prognosis of patients presenting with non-ST-elevation myocardial infarction
Предшестващата анемия е известен предиктор за смърт при пациенти със остър инфаркт на миокарда със SТ-елевация. Данните за влиянието на анемичния синдром са доста по-оскъдни при остър миокарден инфаркт без SТ-елевация (NSTEMI). Цел: Поставихме си за цел да оценим честотата на анемията и влиянието ѝ върху ранните и късните резултати при български пациенти с NSTEMI. Материал и методи: Проведохме амбиспективен анализ на 138 последователни пациенти с NSTEMI, като наличие на анемия се прие при изходен хемоглобин < 120 g/L за жени, < 130 g/L за мъже. Резултати: Няма значима разлика в честота на основните рискови фактори при пациентите със и без анемия. Анемичните пациенти са по възрастни, с по-ниско тегло спрямо ръста и по-лоша изходна бъбречна функция. Изходната анемия е свързана с по-високи стойности на рисковия сбор GRACE и по голям предполагаем размер на реализирания инфаркт според достигнат максимален тропонин І. Няма разлика в приложението на интервенционално лечение. Болничният престой е значително по-дълъг в групата с анемия и е свързан с повече усложнения. Няма разлика в честотата на вътреболничните хеморагични събития и в проведената антиагрегантна терапия, но пациентите с изходна анемия значимо по-често са получили кръвопреливане. Общата смъртност е по-висока при анемичните пациенти както по време на първичния болничен престой, така и по време на проследяването. Заключение: Анемията при постъпването е свързана с повишен риск за усложнен болничен престой и вътреболнична смъртност, както и за влошена отдалечена преживяемост при пациентите с NSTEMI и следва да се включва в общата оценка на риска. Anaemia at admission is a known predictor of death in patients with myocardial infarction with ST-elevation (STEMI). Data on the effect of anaemia on the prognosis in patients with non-ST-elevation myocardial infarction (NSTEMI) is less readily available. Purpose: We aimed to evaluate the frequency of anaemia in a Bulgarian tertiary centre NSTEMI patient population, and its effect on the immediate and extended prognosis of the patients. Methods: We performed ambispective analysis of 138 consecutive patients with NSTEMI, and anaemia was defi ned as haemoglobin at admission below 120 g/L for females and below 130 g/L for males. Results: There was no signifi cant difference in the frequencies of standard risk factors between patients with and without anaemia. Anaemic patients tended to be older, with lower body mass index and worse kidney function. Patients with baseline anaemia tended to have higher GRACE risk scores and a larger size of the realised myocardial infarction as judged by maximal reached troponin I. There was no signifi cant difference in interventional treatment in both groups. Median hospital stay was signifi cantly longer in anaemic patients and was marked by more complications. Despite a lack of increase in inhospital bleeding and no difference in treatment with oral antiaggregants, patients with anaemia received haemotransfusion treatment more often. Mortality rate was higher in anaemic patients both during the index hospitalization and during the follow up. Conclusion: Anaemia at admission is associated with an increased risk of both in hospital cardiovascular complications and after dehospitalisation all-cause mortality in patients with NSTEMI and should be considered as an additional risk factor in the global risk assessment of patients.
- 7 April 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (1) , 65-75
Open AccessImpact of baseline anemia on the short- and long-term prognosis of patients presenting with non-ST-elevation myocardial infarction
Предшестващата анемия е известен предиктор за смърт при пациенти със остър инфаркт на миокарда със SТ-елевация. Данните за влиянието на анемичния синдром са доста по-оскъдни при остър миокарден инфаркт без SТ-елевация (NSTEMI). Цел: Поставихме си за цел да оценим честотата на анемията и влиянието ѝ върху ранните и късните резултати при български пациенти с NSTEMI. Материал и методи: Проведохме амбиспективен анализ на 138 последователни пациенти с NSTEMI, като наличие на анемия се прие при изходен хемоглобин < 120 g/L за жени, < 130 g/L за мъже. Резултати: Няма значима разлика в честота на основните рискови фактори при пациентите със и без анемия. Анемичните пациенти са по възрастни, с по-ниско тегло спрямо ръста и по-лоша изходна бъбречна функция. Изходната анемия е свързана с по-високи стойности на рисковия сбор GRACE и по голям предполагаем размер на реализирания инфаркт според достигнат максимален тропонин І. Няма разлика в приложението на интервенционално лечение. Болничният престой е значително по-дълъг в групата с анемия и е свързан с повече усложнения. Няма разлика в честотата на вътреболничните хеморагични събития и в проведената антиагрегантна терапия, но пациентите с изходна анемия значимо по-често са получили кръвопреливане. Общата смъртност е по-висока при анемичните пациенти както по време на първичния болничен престой, така и по време на проследяването. Заключение: Анемията при постъпването е свързана с повишен риск за усложнен болничен престой и вътреболнична смъртност, както и за влошена отдалечена преживяемост при пациентите с NSTEMI и следва да се включва в общата оценка на риска. Anaemia at admission is a known predictor of death in patients with myocardial infarction with ST-elevation (STEMI). Data on the effect of anaemia on the prognosis in patients with non-ST-elevation myocardial infarction (NSTEMI) is less readily available. Purpose: We aimed to evaluate the frequency of anaemia in a Bulgarian tertiary centre NSTEMI patient population, and its effect on the immediate and extended prognosis of the patients. Methods: We performed ambispective analysis of 138 consecutive patients with NSTEMI, and anaemia was defi ned as haemoglobin at admission below 120 g/L for females and below 130 g/L for males. Results: There was no signifi cant difference in the frequencies of standard risk factors between patients with and without anaemia. Anaemic patients tended to be older, with lower body mass index and worse kidney function. Patients with baseline anaemia tended to have higher GRACE risk scores and a larger size of the realised myocardial infarction as judged by maximal reached troponin I. There was no signifi cant difference in interventional treatment in both groups. Median hospital stay was signifi cantly longer in anaemic patients and was marked by more complications. Despite a lack of increase in inhospital bleeding and no difference in treatment with oral antiaggregants, patients with anaemia received haemotransfusion treatment more often. Mortality rate was higher in anaemic patients both during the index hospitalization and during the follow up. Conclusion: Anaemia at admission is associated with an increased risk of both in hospital cardiovascular complications and after dehospitalisation all-cause mortality in patients with NSTEMI and should be considered as an additional risk factor in the global risk assessment of patients.
- Open Access
- 7 April 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (1) , 86-93
Percutaneous coronary interventions in patients over 80 years old age with acute coronary syndrome
Age is an important non-modifi able risk factor for cardiovascular disease. Both European and American guidelines recommend offering an invasive reperfusion strategy in elderly patients with ACS, taking into account the patients‘ comorbidities and baseline level of functioning. Materials and methods: All patients over 80 years of age with acute coronary syndrome, treated in the Department of Invasive Cardiology of the National Heart Hospital for the period between January 1, 2016. and December 31, 2018, are retrospectively analyzed. The primary endpoint was defi ned as all-cause mortality during the hospital stay and at follow-up. Predictors of mortality were assessed and independent predictors were identifi ed. Results: During the study period, 179 patients aged 80 years or older were identifi ed as being treated for ACS with PCI. In the study population, in hospital mortality for the index event was 11.8%. At a mean follow-up time of 20.19 ± 11.9 months, mortality rose signifi cantly to 64.6%. When evaluating in-hospital mortality on multivariate analysis, the two independent predictors were Cardiogenic shock (HR 0.005, 95% CI 0.01–0.44; p < 0.001) and acute/exacerbated renal failure (0.986 95% CI 0.984-0.997; p = 0.015). Conclusion: The present study provides important information regarding characteristics and outcomes in very elderly patients undergoing PCI for ACS. In the future, this subset of patients is predicted to grow, meaning that their approach must be evidence-based to ensure safe and effective treatment options.
- 7 April 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (1) , 86-93
Open AccessPercutaneous coronary interventions in patients over 80 years old age with acute coronary syndrome
Age is an important non-modifi able risk factor for cardiovascular disease. Both European and American guidelines recommend offering an invasive reperfusion strategy in elderly patients with ACS, taking into account the patients‘ comorbidities and baseline level of functioning. Materials and methods: All patients over 80 years of age with acute coronary syndrome, treated in the Department of Invasive Cardiology of the National Heart Hospital for the period between January 1, 2016. and December 31, 2018, are retrospectively analyzed. The primary endpoint was defi ned as all-cause mortality during the hospital stay and at follow-up. Predictors of mortality were assessed and independent predictors were identifi ed. Results: During the study period, 179 patients aged 80 years or older were identifi ed as being treated for ACS with PCI. In the study population, in hospital mortality for the index event was 11.8%. At a mean follow-up time of 20.19 ± 11.9 months, mortality rose signifi cantly to 64.6%. When evaluating in-hospital mortality on multivariate analysis, the two independent predictors were Cardiogenic shock (HR 0.005, 95% CI 0.01–0.44; p < 0.001) and acute/exacerbated renal failure (0.986 95% CI 0.984-0.997; p = 0.015). Conclusion: The present study provides important information regarding characteristics and outcomes in very elderly patients undergoing PCI for ACS. In the future, this subset of patients is predicted to grow, meaning that their approach must be evidence-based to ensure safe and effective treatment options.
- Open Access
- 21 July 2021
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 27 (2) , 66-71
Тhe uncharted middle ground – when the patient asks, but the guideliness don’t answer
Heart failure takes up an increasing portion of everyday cardiology practice. The accumulation of knowledge about the range of phenotypes and the therapeutic responses across the spectrum of heart failure leads to dynamic reconsideration of the best classifi cation schemes and also of the offi cially recommended therapeutic guidelines. At the moment the lack of clearly structured therapy recommendations for patients with heart failure with mid-range ejection fraction (HFmrEF) poses a lot of questions before the clinician. Their answers, as well as the patient’s clinical stabilization, require a high level of fl uency in latest clinical practices, creative usage of diagnostics and available therapeutics, and competent interdisciplinary long-term follow up. We present a case report of a patient with a relatively typical clinical profi le and suggest a possible therapeutic strategy.
- 21 July 2021
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 27 (2) , 66-71
Open AccessТhe uncharted middle ground – when the patient asks, but the guideliness don’t answer
Heart failure takes up an increasing portion of everyday cardiology practice. The accumulation of knowledge about the range of phenotypes and the therapeutic responses across the spectrum of heart failure leads to dynamic reconsideration of the best classifi cation schemes and also of the offi cially recommended therapeutic guidelines. At the moment the lack of clearly structured therapy recommendations for patients with heart failure with mid-range ejection fraction (HFmrEF) poses a lot of questions before the clinician. Their answers, as well as the patient’s clinical stabilization, require a high level of fl uency in latest clinical practices, creative usage of diagnostics and available therapeutics, and competent interdisciplinary long-term follow up. We present a case report of a patient with a relatively typical clinical profi le and suggest a possible therapeutic strategy.
- Open Access
- 9 October 2020
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 26 (3) , 17-25
Complete interventional revascularization versus infarct-related artery revascularization only in stemi patients – part I
Многоклоновата коронарна болест е честа находка при пациентите, които получават интервенционално изследване и лечение по повод остър миокарден инфаркт със ST-елевация (SТЕМI). Оптималната терапевтична стратегия по отношение на инфарктната лезия е изяснена и е залегнала в редица ръководни правила. Подходът спрямо допълнителните значими коронарни лезии продължава да е обект на дебат и проучвания в световен мащаб както като обем на предприета интервенция, така и като времево позициониране спрямо индексното събитие. Multivessel coronary artery disease is a frequent fi nding during primary PCI procedures in patients with ST-elevation myocardial infarction (STEMI). Optimal therapy of the infarct-related lesion has been largely elucidated and is stipulated in current guideline documents. Therapeutic options for the additional lesions are a subject of active debate and clinical trial worldwide – both the target degree of revascularization and its timing in relation to the index procedure remain unclear.
- 9 October 2020
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 26 (3) , 17-25
Open AccessComplete interventional revascularization versus infarct-related artery revascularization only in stemi patients – part I
Многоклоновата коронарна болест е честа находка при пациентите, които получават интервенционално изследване и лечение по повод остър миокарден инфаркт със ST-елевация (SТЕМI). Оптималната терапевтична стратегия по отношение на инфарктната лезия е изяснена и е залегнала в редица ръководни правила. Подходът спрямо допълнителните значими коронарни лезии продължава да е обект на дебат и проучвания в световен мащаб както като обем на предприета интервенция, така и като времево позициониране спрямо индексното събитие. Multivessel coronary artery disease is a frequent fi nding during primary PCI procedures in patients with ST-elevation myocardial infarction (STEMI). Optimal therapy of the infarct-related lesion has been largely elucidated and is stipulated in current guideline documents. Therapeutic options for the additional lesions are a subject of active debate and clinical trial worldwide – both the target degree of revascularization and its timing in relation to the index procedure remain unclear.